November 2020
Full Citation:
Nourbakhsh B, Revirajan N, Morris B, Cordano C, Creasman J, Manguinao M, Krysko K, Rutatangwa A, Auvray C, Aljarallah S, Jin C, Mowry E, McCulloch C, Waubant E. Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. Lancet Neurol. 2020 Nov 23:S1474-4422(20)30354-9. doi: 10.1016/S1474-4422(20)30354-9. Epub ahead of print. PMID: 33242419.
Publications may either be freely available or require a fee to view (or access) on the journal’s website.
Article Highlight
Fatigue is one of the most common problems among patients living with multiple sclerosis (MS). Three drugs—amantadine, modafinil, and methylphenidate—are commonly prescribed for reducing fatigue in patients with MS, but conclusive evidence for their effectiveness is lacking. As published in Lancet Neurology, this PCORI-funded study led by Bardia Nourbakhsh, MD, at Johns Hopkins University found that these three drugs were no more effective in reducing fatigue in a group of nearly 170 patients with MS than a placebo pill.
Article Type
Paper Resulting From PCORI-Funded Research Study (with results)
CER Results
Literature Type
PCORI Research